<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> is characterized by <z:e sem="disease" ids="C0948379" disease_type="Disease or Syndrome" abbrv="">impaired insulin secretion</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Some but not <z:hpo ids='HP_0000001'>all</z:hpo> studies suggest that a decrease in beta-cell mass contributes to this </plain></SENT>
<SENT sid="2" pm="."><plain>We examined pancreatic tissue from 124 autopsies: 91 <z:mp ids='MP_0001261'>obese</z:mp> cases (BMI &gt;27 kg/m(2); 41 with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, 15 with impaired fasting <z:chebi fb="105" ids="17234">glucose</z:chebi> [IFG], and 35 nondiabetic subjects) and 33 lean cases (BMI &lt;25 kg/m(2); 16 type 2 diabetic and 17 nondiabetic subjects) </plain></SENT>
<SENT sid="3" pm="."><plain>We measured relative beta-cell volume, frequency of beta-cell <z:mpath ids='MPATH_3'>apoptosis</z:mpath> and replication, and new islet formation from exocrine ducts (neogenesis) </plain></SENT>
<SENT sid="4" pm="."><plain>Relative beta-cell volume was increased in <z:mp ids='MP_0001261'>obese</z:mp> versus lean nondiabetic cases (P = 0.05) through the mechanism of increased neogenesis (P &lt; 0.05) </plain></SENT>
<SENT sid="5" pm="."><plain><z:mp ids='MP_0001261'>Obese</z:mp> humans with IFG and type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> had a 40% (P &lt; 0.05) and 63% (P &lt; 0.01) deficit and lean cases of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> had a 41% deficit (P &lt; 0.05) in relative beta-cell volume compared with nondiabetic <z:mp ids='MP_0001261'>obese</z:mp> and lean cases, respectively </plain></SENT>
<SENT sid="6" pm="."><plain>The frequency of beta-cell replication was very low in <z:hpo ids='HP_0000001'>all</z:hpo> cases and no different among groups </plain></SENT>
<SENT sid="7" pm="."><plain>Neogenesis, while increased with <z:hpo ids='HP_0001513'>obesity</z:hpo>, was comparable in <z:mp ids='MP_0001261'>obese</z:mp> type 2 diabetic, IFG, or nondiabetic subjects and in lean type 2 diabetic or nondiabetic subjects </plain></SENT>
<SENT sid="8" pm="."><plain>However, the frequency of beta-cell <z:mpath ids='MPATH_3'>apoptosis</z:mpath> was increased 10-fold in lean and 3-fold in <z:mp ids='MP_0001261'>obese</z:mp> cases of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> compared with their respective nondiabetic control group (P &lt; 0.05) </plain></SENT>
<SENT sid="9" pm="."><plain>We conclude that beta-cell mass is decreased in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> and that the mechanism underlying this is increased beta-cell <z:mpath ids='MPATH_3'>apoptosis</z:mpath> </plain></SENT>
<SENT sid="10" pm="."><plain>Since the major defect leading to a decrease in beta-cell mass in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> is <z:mp ids='MP_0006042'>increased apoptosis</z:mp>, while new islet formation and beta-cell replication are <z:mpath ids='MPATH_458'>normal</z:mpath>, therapeutic approaches designed to arrest <z:mpath ids='MPATH_3'>apoptosis</z:mpath> could be a significant new development in the management of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, because this approach might actually reverse the disease to a degree rather than just palliate glycemia </plain></SENT>
</text></document>